Literature DB >> 7710955

Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma.

P Lipponen1, M Eskelinen, K Syrjänen.   

Abstract

The expression of retinoblastoma (Rb), c-Myc and Bcl-2 proteins was studied by immunohistochemical methods in 104 cases of renal adenocarcinoma. One tumour was completely negative for Rb protein and altered expression pattern was detected in 36% of cases. A low fraction of Rb-positive nuclei was related to high grade (P = 0.016) and high mitotic index (P = 0.012). Twenty-eight per cent of the tumours expressed c-Myc in cancer cell nuclei and 87% showed cytoplasmic positivity. Cytoplasmic expression of c-Myc was related to high grade (P = 0.002), while nuclear expression of c-Myc was related to small tumour diameter (P = 0.034), low T category (P = 0.04), low mitotic index (P = 0.019) and expression of c-ErbB-2 (P = 0.0007). Overexpression of c-myc predicted favourable outcome in M0 tumours (P = 0.0157). Bcl-2 was expressed in 20% of tumours and it was related to small tumour size (P < 0.0001), low T category (P < 0.0001), lack of venous invasion (P = 0.008), node negativity (P = 0.015) and absence of metastasis (P = 0.017). In multivariate analysis the expression of Rb, Bcl-2 and c-Myc had no independent prognostic value over T category (P < 0.001), mitotic index (P = 0.008) and combined nuclear grade (P = 0.056).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710955      PMCID: PMC2033746          DOI: 10.1038/bjc.1995.166

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

1.  A computer program for comparing K samples with right-censored data.

Authors:  E T Lee; M M Desu
Journal:  Comput Programs Biomed       Date:  1972-11

2.  Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues.

Authors:  M Tal; M Wetzler; Z Josefberg; A Deutch; M Gutman; D Assaf; R Kris; Y Shiloh; D Givol; J Schlessinger
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

3.  Noncorrelation of the expression of the c-myc oncogene in colorectal carcinoma with recurrence of disease or patient survival.

Authors:  M D Erisman; S Litwin; R D Keidan; R L Comis; S M Astrin
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

4.  Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies.

Authors:  J Geradts; S X Hu; C E Lincoln; W F Benedict; H J Xu
Journal:  Int J Cancer       Date:  1994-07-15       Impact factor: 7.396

5.  Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas.

Authors:  J Ishikawa; H J Xu; S X Hu; D W Yandell; S Maeda; S Kamidono; W F Benedict; R Takahashi
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

6.  The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status.

Authors:  C Doglioni; A P Dei Tos; L Laurino; C Chiarelli; M Barbareschi; G Viale
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

7.  Ultrastructural characteristics of human renal cell carcinoma in relation to the light microscopic grading.

Authors:  K Syrjänen; L Hjelt
Journal:  Scand J Urol Nephrol       Date:  1978

8.  Cell cycle dependent association of c-myc protein with the nuclear matrix.

Authors:  W Waitz; P Loidl
Journal:  Oncogene       Date:  1991-01       Impact factor: 9.867

9.  Correlation of c-myc expression with nuclear pleomorphism in human renal cell carcinoma.

Authors:  T Kinouchi; S Saiki; T Naoe; A Uenaka; T Kotake; H Shiku; E Nakayama
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

10.  Detection of the c-myc gene product in urinary bladder cancer.

Authors:  T Kotake; S Saiki; T Kinouchi; H Shiku; E Nakayama
Journal:  Jpn J Cancer Res       Date:  1990-12
View more
  5 in total

Review 1.  Histopathological evaluation of apoptosis in cancer.

Authors:  Y Soini; P Pääkkö; V P Lehto
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

2.  Immunohistochemical expression of bcl-2 protein in squamous cell carcinoma and basaloid carcinoma of the esophagus.

Authors:  N Koide; S Koike; W Adachi; J Amano; N Usuda; T Nagata
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

3.  Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo.

Authors:  I Hara; H Miyake; M E Gleave; S Kamidono
Journal:  Jpn J Cancer Res       Date:  2001-11

4.  Is there any potential link among caspase-8, p-p38 MAPK and bcl-2 in clear cell renal cell carcinomas? A comparative immunohistochemical analysis with clinical connotations.

Authors:  Vassilis Samaras; Maria Tsopanomichalou; Angeliki Stamatelli; Christos Arnaoutoglou; Efstathios Samaras; Marianthi Arnaoutoglou; Hercules Poulias; Calypso Barbatis
Journal:  Diagn Pathol       Date:  2009-02-17       Impact factor: 2.644

5.  Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients.

Authors:  T Itoi; K Yamana; V Bilim; K Takahashi; F Tomita
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.